Exenatide/insulin

Drug Profile

Exenatide/insulin

Alternative Names: ORMD 0801/ORMD 0901

Latest Information Update: 17 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oramed Pharmaceuticals
  • Class Antihyperglycaemics; Glucagon-like peptides; Insulins; Pancreatic hormones; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 27 Jun 2017 The Japanese Intellectual Property Office announces intention to grant Oramed Pharmaceuticals a patent for insulin/exenatide for treatment of Diabetes mellitus in Japan
  • 20 Apr 2017 Oramed Pharmaceuticals has patent protection for insulin/exenatide oral combination for Diabetes mellitus in Europe
  • 03 Jan 2013 Preclinical trials in Type-2 diabetes mellitus in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top